Ii. Dementieva et al., THE USE OF HIGH-DOSES OF APROTININ TO DECREASE BLOOD-LOSS IN AORTOCORONARY BYPASS-SURGERY, Journal of Cardiovascular Surgery, 35(6), 1994, pp. 185-186
There were examined 100 patients who had been operated in extracorpore
al circulation for ischemic heart disease. In the Ist group (50 patien
ts), each patient intraoperatively received 6,000,000 KIE of aprotinin
; in the 2nd group (50 patients) placebo. Both groups were similar as
for the age, duration of extracorporeal circulation, and myocardium an
oxia. The total intraoperative blood loss was higher in 2nd group, 638
+/- 5 ml and 952.4 +/- 15.5 ml p < 0.05 correspondingly. The rate of
cases without the intraoperative use of donor blood was 42% in group 1
and 18% in group 2. The postoperative blood loss was significantly lo
wer with the use of aprotinin, 392 +/- 6.6 ml and 689.7 +/- 9.6 ml, p
< 0.05 correspondingly; and in that the Hb concentration in the draina
ge blood was higher in group 2: 31.3 +/- 0.5 g and 73.1 +/- 2.2 g, p <
0.05. In group 1 22% of the patients received donor blood in the earl
y postoperative period, and group 2 twice as many - 56%. Thus prolonge
d intraoperative use of large aprotinin dosages in aortocoronary by-pa
ss surgery is an effective means for stabilization of homeostasis, and
it allows to reduce intra- and postoperative blood loss and diminishe
s the requirements in donor blood.